ĐÁNH GIÁ CHI PHÍ – HIỆU QUẢ CỦA BRENTUXIMAB VEDOTIN TRONG ĐIỀU TRỊ BỆNH NHÂN U LYMPHO HODGKIN TÁI PHÁT/KHÁNG TRỊ BỆNH SAU GHÉP TẾ BÀO GỐC TỰ THÂN TẠI VIỆT NAM

Abstract

Background and Objectives: In Vietnam, annually, there are 651 new cases and 251 cases of mortality due to Hodgkin Lymphoma, with 90% of cases are classical Hodgkin Lymphoma. Currently, brentuximab vedotin (BV) is approved as a salvage treatment for those relapsing/progressing and clinical efficacy of BV has been proven in clinical trials. However, the accessibility is still limited due to the treatment expensive cost. Thus, an economic evaluation for Vietnamese context is necessary. Methods: Partitioned survival model was used in this study to stimulate cost and treatment benefits of using BV compared to traditional chemotherapies. The model utilized inputs from published clinical trial results, Vietnamese sources for cost inputs and verified with clinical opinions. Results: Base case analysis estimated that using BV will cost 399,975,378 VND per patient, increases 1.33 life years and 0.32 quality-adjusted life years. ICER ratios are 22,505,267/LY and 925,845,119/QALY. Conclusions: In comparison with traditional chemotherapies, using BV for CHL post-ASCT relapse/progress patients is not cost-effectiveness in Vietnam. However, as BV treatment cost is the biggest barrier for patients, Vietnamese Health Insurance should consider reimbursing BV to improve equality in healthcare accessibility for relapsed/progressed CHL patients.